Rimonabant, gastrointestinal motility and obesity

Yan Sun, Jiande Chen

Research output: Contribution to journalArticle

Abstract

Background: Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects. Many studies have reported the effects of rimonabant on gastrointestinal (GI) motility and food intake. The aims of this review are: (1) to review the relationship of EC system with GI motility and food intake; (2) to review the studies of rimonabant on GI motility, food intake and obesity; (3) and to report the tolerance and side effects of rimonabant. Methods: the literature (Pubmed database) was searched using keywords: rimonabant, obesity and GI motility. Results: GI motility is related with appetite, food intake and nutrients absorption. The EC system inhibits GI motility, reduces emesis and increases food intake; Rimonabant accelerates gastric emptying and intestinal transition but decreases energy metabolism and food intake. There is rapid onset of tolerance to the prokinetic effect of rimonabant. The main side effects of rimonabant are depression and GI symptoms. Conclusions: Rimonabant has significant effects on energy metabolism and food intake, probably mediated via its effects on GI motility.

Original languageEnglish (US)
Pages (from-to)212-218
Number of pages7
JournalCurrent Neuropharmacology
Volume10
Issue number3
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

rimonabant
Gastrointestinal Motility
Obesity
Eating
Endocannabinoids
Energy Intake
Energy Metabolism
Cannabinoid Receptor Antagonists
Gastric Emptying

Keywords

  • Food intake
  • Gastrointestinal motility
  • Obesity
  • Rimonabant

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Pharmacology
  • Neurology
  • Psychiatry and Mental health

Cite this

Rimonabant, gastrointestinal motility and obesity. / Sun, Yan; Chen, Jiande.

In: Current Neuropharmacology, Vol. 10, No. 3, 2012, p. 212-218.

Research output: Contribution to journalArticle

@article{d53a632decd5489ea02fccea21b836aa,
title = "Rimonabant, gastrointestinal motility and obesity",
abstract = "Background: Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects. Many studies have reported the effects of rimonabant on gastrointestinal (GI) motility and food intake. The aims of this review are: (1) to review the relationship of EC system with GI motility and food intake; (2) to review the studies of rimonabant on GI motility, food intake and obesity; (3) and to report the tolerance and side effects of rimonabant. Methods: the literature (Pubmed database) was searched using keywords: rimonabant, obesity and GI motility. Results: GI motility is related with appetite, food intake and nutrients absorption. The EC system inhibits GI motility, reduces emesis and increases food intake; Rimonabant accelerates gastric emptying and intestinal transition but decreases energy metabolism and food intake. There is rapid onset of tolerance to the prokinetic effect of rimonabant. The main side effects of rimonabant are depression and GI symptoms. Conclusions: Rimonabant has significant effects on energy metabolism and food intake, probably mediated via its effects on GI motility.",
keywords = "Food intake, Gastrointestinal motility, Obesity, Rimonabant",
author = "Yan Sun and Jiande Chen",
year = "2012",
doi = "10.2174/157015912803217297",
language = "English (US)",
volume = "10",
pages = "212--218",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Rimonabant, gastrointestinal motility and obesity

AU - Sun, Yan

AU - Chen, Jiande

PY - 2012

Y1 - 2012

N2 - Background: Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects. Many studies have reported the effects of rimonabant on gastrointestinal (GI) motility and food intake. The aims of this review are: (1) to review the relationship of EC system with GI motility and food intake; (2) to review the studies of rimonabant on GI motility, food intake and obesity; (3) and to report the tolerance and side effects of rimonabant. Methods: the literature (Pubmed database) was searched using keywords: rimonabant, obesity and GI motility. Results: GI motility is related with appetite, food intake and nutrients absorption. The EC system inhibits GI motility, reduces emesis and increases food intake; Rimonabant accelerates gastric emptying and intestinal transition but decreases energy metabolism and food intake. There is rapid onset of tolerance to the prokinetic effect of rimonabant. The main side effects of rimonabant are depression and GI symptoms. Conclusions: Rimonabant has significant effects on energy metabolism and food intake, probably mediated via its effects on GI motility.

AB - Background: Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects. Many studies have reported the effects of rimonabant on gastrointestinal (GI) motility and food intake. The aims of this review are: (1) to review the relationship of EC system with GI motility and food intake; (2) to review the studies of rimonabant on GI motility, food intake and obesity; (3) and to report the tolerance and side effects of rimonabant. Methods: the literature (Pubmed database) was searched using keywords: rimonabant, obesity and GI motility. Results: GI motility is related with appetite, food intake and nutrients absorption. The EC system inhibits GI motility, reduces emesis and increases food intake; Rimonabant accelerates gastric emptying and intestinal transition but decreases energy metabolism and food intake. There is rapid onset of tolerance to the prokinetic effect of rimonabant. The main side effects of rimonabant are depression and GI symptoms. Conclusions: Rimonabant has significant effects on energy metabolism and food intake, probably mediated via its effects on GI motility.

KW - Food intake

KW - Gastrointestinal motility

KW - Obesity

KW - Rimonabant

UR - http://www.scopus.com/inward/record.url?scp=84867536759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867536759&partnerID=8YFLogxK

U2 - 10.2174/157015912803217297

DO - 10.2174/157015912803217297

M3 - Article

C2 - 23449551

AN - SCOPUS:84867536759

VL - 10

SP - 212

EP - 218

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 3

ER -